Results 41 to 50 of about 49,826 (161)

Metabolic effects of sodium-glucose co-transporter 2 inhibitor

Clinical Endocrinology and Endocrine Surgery, 2022
The literature review considers the new universal molecule empagliflozin, which managed to change the glucose‑centric approach in endocrinology to an organoprotective one. The results of the pivotal clinical trials conducted with empagliflozin (EMPA‑REG‑OUTCOME, EMPEROR‑REDUCED, EMPEROR‑PRESERVED and EMPULSE) strongly support the ability of ...
openaire   +2 more sources

ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELLITUS

Juvenis Scientia, 2017
Sodium-glucose co-transporter type 2 inhibitors belong to modern class of oral hypoglycemic drugs, exerting its effect through the reduction of renal glucose reabsorption.
D. A. Lebedev, N. P. Likhonosov, Т. P. Tuchina, V. K. Bayrasheva, A. Yu. Babenko   +4 more
doaj  

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction

JACC: Basic to Translational Science, 2019
Summary: Recent studies send an unambiguous signal that the class of agents known as sodium-glucose–linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear.
Kim A. Connelly, MBBS, PhD, Yanling Zhang, MD, Aylin Visram, BSc, Andrew Advani, BSc, MBChB, PhD, Sri N. Batchu, PhD, Jean-François Desjardins, MSc, Kerri Thai, BSc, Richard E. Gilbert, MBBS, PhD   +7 more
doaj   +1 more source

Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.

PLoS ONE
Several new classes of medications for diabetes have recently become available newer medication classes have been increasing in use. It is unclear how their utilization varied across provinces and how the COVID-19 pandemic may have affected these trends.
Jessica Riad, Fred Abdelmalek, Noah Ivers, Mina Tadrous   +3 more
doaj   +1 more source

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Cardiovascular Diabetology, 2019
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari   +7 more
doaj   +1 more source

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

, 2020
peer ...
Mifsud, Simon, Schembri, Emma Louise, Montebello, Annalisa, Gruppetta, Mark   +3 more
openaire   +1 more source

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight

Indian Journal of Endocrinology and Metabolism, 2015
Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are newly approved class of oral anti-diabetic drugs, in the treatment of type 2 diabetes, which reduces blood glucose through glucouresis via the kidney, independent, and irrespective of available ...
Awadhesh Kumar Singh
doaj   +1 more source

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Cardio-Oncology
Background Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs.
Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, Yasmin Leshem, Or Bainhoren, Tammi Arbel Rubinstein, Maxim Perelman, Zach Rozenbaum, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Ido Wolf, Michal Laufer-Perl   +12 more
doaj   +1 more source

Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation

Frontiers in Pharmacology
Coronary microvascular disease (CMVD) has emerged as a new target for the occurrence and development of heart failure treatment. Various indicators such as Index of Microvascular Resistance, Coronary Flow Reserve, Microvascular Resistance Reserve ...
Shaoxin Chen, Weiqian Ou, Shuguang Gan, Lixian Chen, Baohua Liu, Zhenhong Zhang   +5 more
doaj   +1 more source

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function

Frontiers in Pharmacology, 2022
Daniel H. Van Raalte, Hiddo Lambers Heerspink   +1 more
doaj   +1 more source